Caelyx

Caelyx

doxorubicin

Manufacturer:

Johnson & Johnson
Concise Prescribing Info
Contents
Pegylated liposome encapsulated doxorubicin HCl
Indications/Uses
Monotherapy in metastatic breast cancer where there is an increased cardiac risk. Advanced ovarian cancer in patients who have failed a 1st-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts (<200 CD4 lymphocytes/mm3) & extensive mucocutaneous or visceral disease. 1st-line systemic or 2nd-line chemotherapy in AIDS-KS patients w/ disease that progressed w/ or in patients intolerant to, prior combination systemic chemotherapy comprising of at least 2 of the following: Vinca alkaloid, bleomycin & standard doxorubicin (or other anthracyclines). In combination w/ bortezomib for multiple myeloma patients who have not previously received bortezomib & have received at least 1 prior therapy.
Dosage/Direction for Use
Breast/Ovarian cancer 50 mg/m2 IV every 4 wk for as long as the disease does not progress & patient continues to tolerate treatment. Multiple myeloma 30 mg/m2 on day 4 of the bortezomib 3-wk regimen as a 1-hr infusion administered immediately after the bortezomib infusion. AIDS-KS patient 20 mg/m2 IV every 2-3 wk. Duration of treatment: 2-3 mth.
Contraindications
Hypersensitivity. AIDS-KS that may be effectively treated w/ local therapy or systemic α-interferon. Lactation.
Special Precautions
Do not use interchangeably w/ other formulations of doxorubicin HCl. Frequently monitor ECG. Patients w/ cardiac disease; impaired cardiac function; who have received other anthracyclines. Patients w/ prior mediastinal irradiation or receiving concurrent cyclophosphamide therapy. Perform periodic blood counts frequently. Diabetic patients. Emergency equipment & medications for serious & life-threatening infusion reactions should be available for immediate use. Examine patients for presence of oral ulceration or any oral discomfort that may be indicative of secondary oral cancer. May impair ability to drive & use machines. Hepatic impairment. Pregnancy & lactation. Childn & adolescents <18 yr.
Adverse Reactions
Palmar-plantar erythrodysesthesia, myelosuppression, stomatitis, leukopenia, anemia, neutropenia, thrombocytopenia, nausea, vomiting, neuralgia, peripheral neuropathy, peripheral sensory neuropathy, decreased ejection fraction, fatigue, asthenia, alopecia, fever, diarrhea, infusion-associated acute reactions, opportunistic infections.
Drug Interactions
May potentiate toxicity of other anti-cancer drugs. May exacerbate cyclophosphamide-induced hemorrhagic cystitis & enhance the hepatotoxicity of 6-mercaptopurine.
ATC Classification
L01DB01 - doxorubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Presentation/Packing
Form
Caelyx inj 2 mg/mL
Packing/Price
10 mL x 1's (Rp6,662,300/vial)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in